Navigation Links
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Date:4/1/2008

CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced new data presented at the 57th Annual Scientific Sessions of the American College of Cardiology shows that Ranexa(R) (ranolazine extended release tablets) significantly reduced the risk of recurrent ischemia (p=0.002), worsening angina (p=0.048) and intensification of antianginal therapy (p=0.009) in angina patients (n=3,565) in the MERLIN- TIMI 36 study.

Additionally, Ranexa significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset of 1 mm ST segment depression (p=0.002), a signal of ischemia, in these MERLIN-TIMI 36 angina patients.

"MERLIN-TIMI 36 is the largest study of ranolazine in patients with established coronary artery disease," said David Morrow, M.D., MPH, of Brigham & Women's Hospital at Harvard Medical School and lead investigator of the MERLIN-TIMI 36 study. "This new subgroup analysis shows consistent safety and efficacy across a broader group of angina patients than those studied previously and reaffirms ranolazine as an option for treating chronic angina."

Study Design

MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Previously published data from the MERLIN-TIMI 36 study has shown that Ranexa was safe i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
2. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
3. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
4. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
5. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
6. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
7. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
10. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
11. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Colo. , July 27, 2015 /PRNewswire/ ... report financial results for the fourth quarter ... hold a conference call to discuss those ... Squarer, Chief Executive Officer will lead the ... a.m. Eastern TimeToll-Free:(844) 464-3927Toll:(765) 507-2598Pass Code: 68380312 ...
(Date:7/27/2015)... 27, 2015 As per the new ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 ... billion in 2014, growing at a CAGR of 13.2% from ... 2021. The global bionics market is growing primarily ... is leading to paralysis or amputation of body parts. In ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ) has ... in Asia/Pacific Markets Seminar" conference to their offering. ... market is well established, the next growth area is ... , together with other countries in this region have ... their own medical device regulations. This seminar will provide ...
Breaking Medicine Technology:Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2
... PDS Biotechnology Corporation today,announced that the company ... the US,National Cancer Institute,s Nanotechnology Characterization Lab ... to filing of,the Investigational New Drug Application. ... biological studies on behalf of the company ...
... completed a clinical safety report from a large Phase ... the excellent,safety profile of IMVAMUNE(R). Within the next few ... to the FDA and this will trigger a USD ... safety,report constitutes a major part of the data package ...
Cached Medicine Technology:PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies 2Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) 2
(Date:7/28/2015)... ... 2015 , ... Women fear developing Alzheimer's disease more than having a heart ... stroke are treatable, but there is little an individual can do to arrest the ... a clinical trial, reports the July 2015 Harvard Women's Health Watch . , ...
(Date:7/28/2015)... ... , ... A new study published by HealthDay News on June 24, 2015, ... a possible new treatment option for people living with fibromyalgia – hyperbaric oxygen therapy ... five per week, patients experienced a significant decrease in pain, fatigue, and other symptoms ...
(Date:7/28/2015)... IN (PRWEB) , ... July 28, 2015 , ... Most ... released from the 2014 UBA Health Plan Survey shows a significant increase in the ... major increases in corresponding median copays -- a trend that is expected to continue, ...
(Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys ... the regional winner of the EY Entrepreneur of the Year award. The award ... of home healthcare, and the innovative work they have done in incorporating new ...
(Date:7/28/2015)... Maryland (PRWEB) , ... July 28, 2015 , ... Maryland ... (MBSP) – and, along with it, more service offerings, updated treatment techniques, and ... leading authority for pain management and minimally invasive surgical treatment of brain and spine ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4
... discover gender differences that explain the aging inequity ... discovered yet another gender inequity: Women develop more and ... men do. , The disadvantage had long been suspected, ... Dr. Foad Nahai, a plastic surgeon practicing in Atlanta ...
... , , GAINESVILLE, Fla., Dec. 17 Over the last ... scare language that is used by e cigarette opposition in an ... questioning the tactics of these groups when the evidence clearly shows ... to several studies, lab reports and opinions from top medial and ...
... , , HOUSTON, ... Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin ... for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic ... late-stage development - the rights to which have been ...
... ... the nearly one-in-three American adults who serve as a family caregiver , ... Arlington, VA (PRWEB) December 17, 2009 -- The ... 2009 , which offers a revealing portrait of the nearly one-in-three American adults who serve ...
... ... Google Local and in front of their local customers by establishing a simple and ... Internet Marketing. , ... New Orleans, LA (PRWEB) December 17, 2009 -- In order to be competitive locally ...
... , ... Using new marketing techniques, life coaching company puts free i-phone & i-touch application ... , ... (PRWEB) December 17, 2009 -- Utah based Attainment Life Management & Coaching is ...
Cached Medicine News:Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2Health News:Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: